111, Inc. partners with Chugai Pharma China Ltd to fast-track innovations in chronic disease management

CHINA – 111, Inc., a leading tech-enabled healthcare platform company dedicated to digitally connecting patients with medicine and healthcare services in China, has announced a strategic cooperation agreement with Chugai Pharma China Co., Ltd., to accelerate innovations in chronic disease management. Chronic disease has become an epidemic. The vast majority of annual health-care spending is spent on treating diseases such as heart disease, cancer, diabetes, and obesity. Nonetheless, despite trillions of dollars spent on management, chronic diseases persist. The agreement will enable 111 and Chugai Pharma China to collaborate in…

Read More

Click Therapeutic secures US$52 million in Series B funding to expand prescription portfolio

USA – Click Therapeutic, a prescription digital therapeutic company, has bagged US$52 million Series B funding round led by Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures, and RidgetopHealth. Other participants included Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures, and RidgetopHealth. This announcement comes more than a year after the company signed a US$500 million-plus deal with pharmaceutical company Boehringer Ingelheim to jointly commercialize a digital treatment for schizophrenia patients. Click’s pipeline of innovative digital therapeutics covers a wide range of therapeutic areas, including psychiatry…

Read More

Rare nervous system syndrome linked to AZ’s Covid -19 jab

UNITED KINGDOM – The Medicines and Healthcare products Regulatory Agency (MHRA) has added Guillain-Barré syndrome, a rare nervous system syndrome, as a possible side effect of the AstraZeneca COVID vaccine. Guillain-Barré syndrome (GBS) is a rare autoimmune disorder in which a person’s own immune system attacks their nerves, causing weakness and, in severe cases, paralysis. According to the NHS, the disease primarily affects nerves in the feet, hands, and limbs, and symptoms can last from a few weeks to several years. Most people recover completely, but some may suffer permanent…

Read More

AstraZeneca cancer drug improves survival rate in liver cancer patients

UNITED KINGDOM – AstraZeneca PLC has reported its trial of the cancer drug Imfinzi (Durvalumab) showed a “statistically significant and clinically meaningful overall survival benefit” when compared to chemotherapy alone. The positive results of the Topaz-1 Phase III trial demonstrated that Imfinzi was effective as a treatment for patients with advanced biliary tract cancer when combined with standard-of-care chemotherapy. According to Astra, the trial met the primary endpoint by demonstrating an improvement in overall survival as well as improvements in progression-free survival and overall response rate, which are key secondary…

Read More

WHO’s advisory group to deliberate on Covaxin EUL approval

SWITZERLAND – The World Health Organization (WHO) has announced that experts will meet on October 26 to decide whether to grant emergency use status to Bharat Biotech’s Covid-19 vaccine Covaxin. Harsh Vardhan Shringla, India’s foreign secretary, expressed optimism that the WHO will soon approve Hyderabad-based Bharat Biotech’s Covid vaccine Covaxin. “It is not the administrative or political process, rather it is a technical process of WHO. Technical Committee will evaluate the submissions made by Bharat Biotech which created Covaxin. I am sure the approval of Covaxin from WHO will come…

Read More

Sanofi scores sixth win for its versatile monoclonal antibody drug

FRANCE – Regeneron Pharmaceuticals and French major, Sanofi, have announced positive pivotal Phase 3 results from a trial evaluating Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease characterized by severe itching and skin lesions. The trial of the blockbuster met its primary and all key secondary endpoints, demonstrating that Dupixent significantly reduced itch and skin lesions in this investigational setting when compared to placebo. Uncontrolled prurigo nodularis has the highest impact on quality of life of any inflammatory skin disease with intense, chronic…

Read More

Medtronic appoints new Chief Medical Officer for GIT business

IRELAND – Medtronic plc, a global leader in healthcare technology, has hired Dr. Austin L. Chiang, as Chief Medical Officer (CMO) of the Gastrointestinal (GI) business at Medtronic. Chiang is an assistant professor of medicine at Sidney Kimmel Medical College and director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, both in Philadelphia. He has a master’s degree in public health from the Harvard T.H. Chan School of Public Health. Dr. Chiang, a nationally recognized gastroenterologist and advanced endoscopist, is passionate about providing accurate medical information to patients…

Read More

Remote glaucoma care Implandata voted among top 12 techpreneurs

GERMANY – Implandata Ophthalmic Products, a digital health eye care company, has been named a top 12 health techpreneur at the Medica Healthcare Innovation World Cup, the world’s largest medical trade fair. Implandata was named a leading breakthrough health care innovator among more than 300 competitors and has been invited to present its disruptive Eyemate solution at the Medica Connected Health Care Forum on November 15th, 2021. Earlier in 2021, the US FDA granted Breakthrough Device Designation. The system allows patients to self-measure critical disease parameters and then automatically sends…

Read More

New targets for glaucoma treatment identified in mice models-Study

USA – A Northwestern Medicine study’s findings could lead to an effective glaucoma treatment, which would be a significant step forward in the fight against the condition. The Northwestern University Fienberg School of Medicine researchers used mouse models to identify novel glaucoma treatment targets, such as preventing a severe pediatric form of the condition. The groundbreaking study also discovered a potential new class of glaucoma treatment for the most common form of the disease in adults. The findings are published in the journal Nature Communications in a paper titled, “Cellular…

Read More

WHO releases recommendations for robust healthcare delivery post-covid

SWITZERLAND – The World Health Organization (WHO) in a novel paper has identified seven critical areas that must be strengthened in order to improve health services worldwide. Throughout the COVID-19 pandemic, health services were exhausted and stretched far beyond their capacity; now, the World Health Organization has released its seven recommendations for ensuring the future of health systems in the aftermath of the last two years of devastation. The WHO believes that this effort will help to accelerate the implementation of the International Health Regulations (2005), advancing health systems toward…

Read More